TRANSPLANTATION AND CELLULAR ENGINEERING: Adipose tissue mesenchymal stem cell expansion in animal serum‐free medium supplemented with autologous human platelet lysate

Blande, Ivan Souza; Bassaneze, Vinícius; Lavini-Ramos, Carolina; Faé, Kellen C.; Kalil, Jorge; Miyakawa, Ayumi Aurea; Schettert, Isolmar Tadeu; Krieger, José Eduardo

doi:10.1111/j.1537-2995.2009.02346.x

Cited by 104 publications

(87 citation statements)

References 18 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VBD concentrations added to culture medium ranged from 0.5 to 30% (54)(55)(56). Overall, VBD allowed for either, maintenance of MCS's fibroblast-like morphology (17,43,57), high proliferation (58-60), high colony-formation ability (52,61,62) and maintenance of multipotency (63)(64)(65)(66)(67). A linear dose-dependent response regarding medium concentration was not observed for evaluated VBD (54,56,68).…”

Section: Resultsmentioning

confidence: 97%

“…HS 10% expanded DPSC were capable of regenerating more mineral tissue than those 10% FBS-expanded in vivo (48). The studies reported 5% (68) and 10% (12) as being the optimal HPL concentration range for MSC expansion (12,54,64,114). Moreover, different VBD concentration (0.5-30%) have been tested presenting different results, which have not been necessarily dose-dependent (54)(55)(56).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

et al. 2017

View full text Add to dashboard Cite

Although the biological properties of mesenchymal stem cells (MSC) are well-characterized in vitro, MSC clinical application is still far away to be achieved, mainly due to the need of xenogeneic substances for cell expansion, such as fetal bovine serum (FBS). FBS presents risks regarding pathogens transmissions and internalization of animal's proteins, which can unleash antigenic responses in patients after MSC implantation. A wide range of venous blood derivatives (VBD) has been reported as FBS substitutes showing promising results. Thus, the aim of this study was to conduct a systematic scoping review to analyze whether VBD are effective FBS substitutes for MSC ex vivo expansion. The search was performed in SciVerse Scopus TM , PubMed, Web of Science TM , BIREME, Cochrane library up to January 2016. The keywords were selected using MeSH and entry terms. Two independent reviewers scrutinized the records obtained considering specific inclusion criteria. The included studies were evaluated in accordance with a modified Arksey and O' Malley's framework. From 184 found studies, 90 were included. Bone marrow mesenchymal stem cells (BMMSC) were presented in most of these studies. Overall, VBD allowed for either, maintenance of MCS's fibroblast-like morphology, high proliferation, high colony-formation ability and maintenance of multipotency. Besides. MSC expanded in VBD supplements presented higher mitogen activity than FBS. VBD seems to be excellent xeno-free serum for ex vivo expansion of mesenchymal stem cells. However, an accentuated heterogeneity was observed between the carried out protocols for VBD isolation did not allowing for direct comparisons between the included studies.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…After excluding reviews and articles pertaining to dental and bone biology, and adding hand search relevant articles, we included 57 articles as relevant to research in biological mechanisms, of which 22 articles perform large scale MSC production. Twelve articles perform studies on Adipose Stem Cells (ADSCs) [7][8][9][10][11][12][13][14][15][16][17][18] …”

Section: Study Selectionmentioning

confidence: 99%

Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience

Rubio‐Azpeitia

Andı́a

2014

MLTJ

View full text Add to dashboard Cite

SummaryWe aim to identify current in vitro research exploring platelet-rich plasma (PRP) effects in human Mesenchymal Stem Cells (MSCs) that may encourage or limit the clinical application of MSCs along with PRP. After a systematic search, we identified 57 in vitro studies, focused on optimization of MSC manufacturing, and expanding knowledge about how PRP modifies MSCs behavior for translational purposes. Influences of PRP on proliferation, migration, stemness, preservation of MSC immune-modulatory properties and appearance of senescence phenotype have been explored. Overall PRP stimulates MSC proliferation, preserves MSCs multipotency and does not interfere with any lineage differentiation. PRP (as platelet lysate or releasate) preserves the immune-privileged potential of MSCs and may delay the appearance of the senescent phenotype. Currently there are few data linking precise molecules and biological mechanisms. Various gaps of knowledge need to be addressed in order to obtain enough useful information for translational purposes.

show abstract

“…Human platelet lysate (HPL) has been used in the past few years as an alternative to FBS for GMP-compliant ASC expansion and is being used in several clinical trials (3,15,18,19). Both autologous (recipient-derived) and allogeneic (donor-derived) HPL have been investigated for ASC expansion with favourable outcomes (20,21). While autologous platelet lysate negates the need for testing for disease-causing agents, it is not always possible to produce sufficient volumes for expansion of ASCs.…”

Section: Introductionmentioning

confidence: 99%

Comparison of human platelet lysate alternatives using expired and freshly isolated platelet concentrates for adipose-derived stromal cell expansion

2018

View full text Add to dashboard Cite

Pooled human platelet lysate (pHPL) has been used to expand adipose-derived stromal cells (ASCs) and can be formulated using fresh or expired buffy coats (BCs) which are then resuspended in either plasma or an additive solution. Not much is known about the effects that expired products and additive solutions have on ASC expansion, and the need for quality control and release criteria has been expressed. This pilot study compared proliferation, cell size, morphology and immunophenotype of ASCs expanded in the different pHPL alternatives versus foetal bovine serum (FBS). Quality control criteria were assessed prior to and during the manufacture of the pHPL alternatives. ASCs were then expanded in 1%, 2.5%, 5% or 10% of the different pHPL alternatives or in 10% FBS. Cell size, morphology, cell number and immunophenotype were measured using microscopy and flow cytometry. The majority of the pHPL alternatives were within the recommended ranges for the quality control criteria. ASCs expanded in the pHPL alternatives were smaller in size, displayed a tighter spindle-shaped morphology, increased cell growth and had a similar immunophenotype (with the exception of CD34 and CD36) when compared to ASCs expanded in FBS. Here we report on the effects that expired BC products and additive solutions have on ASC expansion. When taken together, our findings indicate that all of the pHPL alternatives can be considered to be suitable replacements for FBS for ASC expansion, and that expired BC products can be used as an alternative to fresh BC products. KeywordsAdditive solution, adipose-derived stromal cells, expired buffy coats, foetal bovine serum, pooled human platelet lysate History

show abstract

TRANSPLANTATION AND CELLULAR ENGINEERING: Adipose tissue mesenchymal stem cell expansion in animal serum‐free medium supplemented with autologous human platelet lysate

Abstract: Taken together, evidence is provided that platelets provided by a single donor are sufficient to obtain PL for hASC propagation for clinical-scale applications mitigating the potential untoward side effects associated with the use of animal-derived reagents.

Cited by 104 publications

References 18 publications

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience

Comparison of human platelet lysate alternatives using expired and freshly isolated platelet concentrates for adipose-derived stromal cell expansion

Contact Info

Product

Resources

About